A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection (Q40344161)

19 September 2017

A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection (English)

1 reference

19 September 2017

0 references

1 reference

8

Michael S Diamond

0 references

Brian J Geiss

object named as

Brian J Geiss

5

0 references

Theodore C Pierson

1

object named as

Theodore C Pierson

1 reference

19 September 2017

3

Bridget A Puffer

1 reference

19 September 2017

Laura Staun Valentiner

6

object named as

Laura E Valentine

1 reference

19 September 2017

Melissa D Sánchez

2

1 reference

19 September 2017

Asim A Ahmed

4

1 reference

19 September 2017

Louis A Altamura

7

1 reference

19 September 2017

Robert W Doms

9

1 reference

19 September 2017

language of work or name

English

0 references

publication date

2 December 2005

1 reference

19 September 2017

1 reference

19 September 2017

346

1 reference

19 September 2017

1

1 reference

19 September 2017

53-65

1 reference

Two Distinct Size Classes of Immature and Mature Subviral Particles from Tick-Borne Encephalitis Virus

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

The molecular biology of West Nile Virus: a new invader of the western hemisphere

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Clinical characteristics of the West Nile fever outbreak, Israel, 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

West Nile Virus Discriminates between DC-SIGN and DC-SIGNR for Cellular Attachment and Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Innate and Adaptive Immune Responses Determine Protection against Disseminated Infection by West Nile Encephalitis Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Incorporation of Tick-Borne Encephalitis Virus Replicons into Virus-Like Particles by a Packaging Cell Line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Two monoclonal antibodies against La Crosse virus show host-dependent neutralizing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

West Nile virus: where are we now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Neutralization and antibody-dependent enhancement of dengue viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

N-Linked Glycosylation of West Nile Virus Envelope Proteins Influences Particle Assembly and Infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Tetracycline-inducible packaging cell line for production of flavivirus replicon particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Construction and applications of yellow fever virus replicons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

A hypothesis accounting for the effect of the host cell on neutralization-resistant virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Influence of host cells on the infectivity and neutralizability echovirus type 4 (Pesascek).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Occupancy and mechanism in antibody-mediated neutralization of animal viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage In vitro is lethal for virus production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

A live attenuated West Nile virus strain as a potential veterinary vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

West Nile encephalitis: an emerging disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Complement activation is required for induction of a protective antibody response against West Nile virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

A ligand-binding pocket in the dengue virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Structure of West Nile Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

A structural perspective of the flavivirus life cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

The outbreak of West Nile virus infection in the New York City area in 1999

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

An infectious West Nile virus that expresses a GFP reporter gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Antibody prophylaxis and therapy for flavivirus encephalitis infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Characterization of neutralizing antibodies to West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

trans-Packaged West Nile virus-like particles: infectious properties in vitro and in infected mosquito vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Studies on the nature of dengue viruses. IV. The structural proteins of type 2 dengue virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

West Nile encephalitis epidemic in southeastern Romania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

DNA vaccine for West Nile virus infection in fish crows (Corvus ossifragus).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Noncytopathic flavivirus replicon RNA-based system for expression and delivery of heterologous genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Studies on virus-specific nucleic acids synthesized in vertebrate and mosquito cells infected with flaviviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

An infectious clone of the West Nile flavivirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

Analysis of extracellular West Nile virus particles produced by cell cultures from genetically resistant and susceptible mice indicates enhanced amplification of defective interfering particles by resistant cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Physical and biological properties of dengue-2 virus and associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.10.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.10.030

1 reference

19 September 2017

1 reference